Cardiovascular Genistein Therapy for Heart Failure Inflammation

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

September 1, 2026

Conditions
Heart Failure
Interventions
DRUG

Genistein

Escalation genistein dosing, followed by wash-out period

Trial Locations (1)

1000

RECRUITING

UMC Ljubljana, Ljubljana

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Greenstone Biosciences

UNKNOWN

lead

University Medical Centre Ljubljana

OTHER